We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Trillium Therapeutics Inc | NASDAQ:TRIL | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 18.44 | 20.33 | 18.30 | 0 | 01:00:00 |
“We are delighted to welcome Mr. Pucci to the board of directors” said Robert L. Kirkman, M.D., Chair of Trillium Therapeutics. “His broad executive and commercial expertise, specifically in the field of oncology, will be invaluable as Trillium prepares for later stage clinical development.”
Most recently, Mr. Pucci served as Chief Executive Officer of the targeted therapeutics oncology company, ArQule, until it was acquired by Merck for $2.7 billion in January 2020. Prior to ArQule, Mr. Pucci served in a number of leadership positions at Bayer AG from 2001 to 2008, including President of the Oncology & Global Specialty Medicines Business Units and was a member of the Bayer Pharmaceuticals Global Management Committee. Mr. Pucci also held multiple roles at Eli Lily and Company from 1991 to 2001.
Mr. Pucci received his M.S. in economics and accounting from Università degli Studi di Napoli Federico II and an MBA in marketing and finance from the University of Chicago. He currently serves as a board member of West Pharmaceuticals Services Inc., Merus N.V. and Replimune Inc., and had previous board roles at NewLink Genetics Inc., Dyax Inc. and Algeta ASA.
“I look forward to contributing my knowledge in oncology drug development and commercialization over the coming years,” said Mr. Pucci. “There has never been a more exciting time to be developing novel oncology agents, and Trillium is well positioned in the field.”
About Trillium Therapeutics
Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s two clinical programs, TTI-621 and TTI-622, target CD47, a “don’t eat me” signal that cancer cells frequently use to evade the immune system.
For more information visit: www.trilliumtherapeutics.com
Investor Relations:James ParsonsChief Financial OfficerTrillium Therapeutics Inc. 416-595-0627 x232james@trilliumtherapeutics.com www.trilliumtherapeutics.com
Media Relations:Mike BeyerSam Brown Inc.312-961-2502mikebeyer@sambrown.com
1 Year Trillium Therapeutics Chart |
1 Month Trillium Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions